Metrics as of 10/17/2026, 08:29 AM (Berlin time), refresh in progress.
Biogen Stock
Biogen Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- CEO
- Christopher A. Viehbacher
- Employees
- 7,500
- Market cap
- $34.4 B
- IPO
- 17/09/1991
Biogen Inc. (BIIB) is a US-based healthcare company in the drug manufacturers - general sector, headquartered in Cambridge, Massachusetts. The company's portfolio focuses on developing therapies for complex neurological and neurodegenerative diseases such as multiple sclerosis, spinal muscular atrophy, or Alzheimer's.…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Biogen stock: price history
1D
-1.1%
1W
+3.1%
1M
+7.7%
6M
+31.2%
YTD
+32.2%
1Y
+63.5%
2Y
+23.1%
5Y
-17.3%
10Y
-19.9%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~5% weaker price swings than usual
Biogen stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Biogen Inc. is a specialized biotechnology company focused on researching, developing, and commercializing therapies for complex neurological and neurodegenerative diseases. The portfolio includes medicines for treating multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, as well as various biosimilars such as Benepali and Imraldi. Beyond established products, the company maintains an extensive research pipeline for indications including Parkinson's disease, neuropsychiatric disorders, and immunology. Business operations span the US market as well as significant international business.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Denali Therapeutics Inc.Description
Ionis Pharmaceuticals, Inc.DescriptionAsk the agents about Biogen
Analyst assessment of Biogen
PRICE TARGET LOW
US$175.00
CONSENSUS
US$245.88
MEDIAN
US$248.00
PRICE TARGET HIGH
US$300.00
0
STRONG BUY
32
BUY
16
HOLD
1
SELL
0
STRONG SELL
49
TOTAL · Buy
As of: 12/10/2026
Biogen stock metrics
P/E
40.96
P/B
1.82
EV/EBITDA
21.19
RETURN ON EQUITY
0.5%
NET MARGIN
3.6%
DEBT/EQUITY
0.44
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.2%
FLOAT SHARES
146,639,196
AVG. DAILY VOLUME (30D)
1,142,387
Insider transactions (SEC)
Godbout Sean
Godbout Sean
Minor Lloyd
Minor Lloyd
Patolawala Monish D
Attention
Price since yesterday: -1.1%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Biogen stock
What does Biogen do?
Biogen Inc. is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is Christopher A. Viehbacher, the company employs around 7,500 people.
The IPO was on 17/09/1991; the stock trades on NASDAQ under the ticker BIIB.
What do analysts say about Biogen stock?
49 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$245.88, ranging from US$175.00 to US$300.00, with a median of US$248.00.
This is an external assessment, not a statement by Market Jury.
When does Biogen report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly -5% stronger than usual.
Does Biogen pay a dividend?
No, Biogen currently does not pay a dividend.
Which stocks are comparable to Biogen?
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Amgen, Gilead Sciences, Pfizer and Bristol-Myers Squibb Company.
How can I get Biogen stock analyzed?
Clicking "Analyze stock" lets five strategies assess Biogen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.